Skip to main content
Industry News
Combo doesn't slow familial adenomatous polyposis

Eflornithine and sulindac combined did not significantly halt progression of familial adenomatous polyposis better than treatment with either of the drugs alone, according to a study led by ACG Past President Carol Burke, MD, FACG, of the department of gastroenterology, hepatology and nutrition at the Cleveland Clinic and published in The New England Journal of Medicine. "Additional studies that focus on clinical end points in the lower gastrointestinal tract are warranted to better understand the potential of this combination therapy for pharmacologic prevention in specific groups of patients with familial adenomatous polyposis, especially those who have not yet undergone prophylactic colectomy," researchers wrote.

Full Story: